Editas medicine stock price.

Phil Nadeau’s Buy rating for Editas Medicine’s stock is premised on a variety of factors. Key among these is the company’s strong financial position, with reported cash reserves of $446 ...Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.The average price recommended by analysts for Editas Medicine Inc (EDIT) is $13.93, which is $3.19 above the current market price. The public float for EDIT is 81.05M and currently, short sellers hold a 19.58% of that float. On November 29, 2023, EDIT’s average trading volume was 1.64M shares. EDIT) stock’s latest price updateNov 30, 2023 · View Editas Medicine, Inc EDIT investment & stock information. Get the latest Editas Medicine, Inc EDIT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Editas Medicine (EDIT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $0.57 per share a year ago. These figures ...Consider, for instance, Editas Medicine (EDIT-6.20%) ... Stock Advisor list price is $199 per year. Join Stock Advisor Cumulative Growth of a $10,000 Investment in Stock Advisor.

Summary of all time highs, changes and price drops for Editas Medicine; Historical stock prices; Current Share Price: US$10.77: 52 Week High: US$11.93: 52 Week Low ...

11.34%. Get the latest Editas Medicine Inc (EDIT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment... Jan 13, 2022 · Shares of Editas Medicine (EDIT 3.76%) were tumbling 13% lower this week as of the market close on Thursday, ... Stock Advisor list price is $199 per year. Join Stock Advisor Editas Medicine, Inc. (EDIT) is a clinical-stage genome editing company that develops treatments for cancer and other diseases. The stock price, news, quote and history of EDIT are shown on Yahoo Finance. See the latest performance outlook, earnings date, dividend yield, fair value and more. Summary of all time highs, changes and price drops for Editas Medicine; Historical stock prices; Current Share Price: US$10.77: 52 Week High: US$11.93: 52 Week Low ...Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Editas Medicine Inc. analyst ratings, historical stock prices, earnings estimates & actuals. EDIT updated stock price target summary.

The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.

Complete Editas Medicine Inc. stock information by Barron's. View real-time EDIT stock price and news, along with industry-best analysis.Editas Medicine, Inc. (EDIT) Stock Price, Quote, News & Analysis EDIT Editas Medicine, Inc. Stock Price & Overview 38.49K followers $10.53 -0.08 ( -0.75%) …The Editas Medicine stock forecast for tomorrow is $ 10.59, which would represent a 0.59% gain compared to the current price. In the next week, the price of EDIT is expected to decrease by -23.77% and hit $ 8.03. As far as the long-term Editas Medicine stock forecast is concerned, here’s what our predictions are currently suggesting.Oct 2, 2023 · Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. By Alex Carchidi – Oct 2, 2023 at 10:00AM ... Current Price. $10.77. Price as of December 1, 2023, 4:00 p.m. ET. Editas Medicine Inc. Real-Time Quotes. 10.68. BATS BZX Real-Time Price. As of 3:23pm ET. +0.15 / +1.42%. Today’s Change. 6.08. Today ||| 52-Week Range.With all that said, here are the most exciting genomic stocks that you won’t want to miss out on. NTLA Intellia Therapeutics $37.75 BEAM Beam Therapeutics $30.71 EDIT Editas Medicine $8.16.Current Price. $10.65. Price as of November 27, 2023, 4:00 p.m. ET. Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now? You can't ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geulah Livshits from Chardan Capital remains neutral on the stock ...Price is a widely used stock evaluation measure. Find the latest Price for Editas Medicine (EDIT) ... Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates 11/03/23-7:45AM EST ZacksEditas Medicine Inc. analyst ratings, historical stock prices, earnings estimates & actuals. EDIT updated stock price target summary.The Editas Medicine stock forecast is 21.770642845038 USD for 2024 November 30, Saturday; and 92.327 USD for 2028 November 30, Thursday with technical analysis. Editas Medicine (EDIT) stock price prediction is 21.770642845038 USD.Jan 10, 2023 · In the last 3 months, 18 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $19.17 with a high of $43.00 and a low of $6.00. Editas got a bump on Sept. 29 when Stifel analyst Dae Gon Ha increased his 12-month price target for Editas from $9 to $17 and upgraded his position on the biotech stock from hold to buy, saying ...

Editas Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 03. CI. North American Morning Briefing : S&P 500 Futures -2-. Nov. 03. DJ. Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored ... Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 17.03% so far this month. During the month of May, Editas Medicine Inc’s stock price has reached a high of $10.71 and a low of $7.69. Over the last year, Editas Medicine Inc has hit prices as high as $19.97 and as low as $6.33. Year to date, Editas Medicine ...

By contrast, Bluebird and Editas shares both fell by over 50% over the first six months of 2022, while CRISPR's stock price stumbled by a noteworthy 20% during the first half of the year. Image ...Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company …Nov 21, 2023 · Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 51.5% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $11.14 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $11.93 and as low as $6.08. Year to date, Editas ... What's more, shares of CRISPR Therapeutics (CRSP-6.39%) have gained 22.6% over the same period, and fellow gene editor Editas Medicine (EDIT-6.64%) also saw its equity rise in price by a healthy ...Find out the current price target and stock forecast for Editas Medicine ... Based on short-term price targets offered by 13 analysts, the average price target for Editas Medicine comes to $13.85 ...Editas Medicine ended the third quarter with $478.5 million in cash and equivalents, compared to $657 million as of Q3 2021. It reported a net loss of $55.7 million during the period, worse than ...Market Cap. $422M. Today's Change. (0.52%) $0.02. Current Price. $3.86. Price as of November 29, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may differ from The Motley ...

Our information suggests that Editas Medicine, Inc. insiders own under 1% of the company. It appears that the board holds about US$2.6m worth of stock. This …

Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.

Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Nov 24, 2023 · Editas Medicine Stock Forecast 11-26-2023. Forecast target price for 11-26-2023: $ 10.97. Positive dynamics for Editas Medicine shares will prevail with possible volatility of 3.528%. Pessimistic target level: 10.80. Optimistic target level: 11.19. The Editas Medicine stock forecast for tomorrow is $ 10.59, which would represent a 0.59% gain compared to the current price. In the next week, the price of EDIT is expected to decrease by -23.77% and hit $ 8.03. As far as the long-term Editas Medicine stock forecast is concerned, here’s what our predictions are currently suggesting. Shares of Editas Medicine (EDIT 3.66%) ... which have yet to be adequately reflected in stock prices. Of course, the flip side is that the merger doesn't make as much sense for Beam Therapeutics. ...Shares of Editas Medicine (EDIT 3.66%) ... which have yet to be adequately reflected in stock prices. Of course, the flip side is that the merger doesn't make as much sense for Beam Therapeutics. ...In the last 3 months, 6 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $14.67 with a high of $22.00 and a low of $8.00.CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to …What's more, shares of CRISPR Therapeutics (CRSP-6.39%) have gained 22.6% over the same period, and fellow gene editor Editas Medicine (EDIT-6.64%) also saw its equity rise in price by a healthy ...

CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses.Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.Feb 2, 2023 · Why Editas Medicine Stock Charged Higher in January. By George Budwell – Feb 2, 2023 at 11:33AM Key Points. ... Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. Instagram:https://instagram. 1964 jfk half dollar valueblackrock esg investingnasdaq hopebest discount brokerage canada Based on short-term price targets offered by 13 analysts, the average price target for Editas Medicine comes to $13.85. The forecasts range from a low of $7.00 to a high of $30.00. The average ...Editas Medicine, Inc. (EDIT) is a clinical-stage genome editing company that develops treatments for cancer and other diseases. The stock price, news, quote and history of EDIT are shown on Yahoo Finance. See the latest performance outlook, earnings date, dividend yield, fair value and more. no load index fundsbest futures trading platform for beginners Editas Medicine Inc (EDIT) stock is trading at $10.90 as of 12:05 PM on Wednesday, Nov 29, a rise of $0.16, or 1.49% from the previous closing price of $10.74. …On June 15, Editas Medicine ( EDIT 2.23%) saw its shares collapse by 15% after announcing it would be issuing new stock to raise approximately $125 million. The biotech will almost certainly use ... federal tax brackets 2024 Nov 20, 2022 · Price as of December 1, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street. View live Editas Medicine, Inc. chart to track its stock's price action. Find market predictions, EDIT financials and market news.Gene editing stocks rallied Thursday as Wall Street took notice of the underperforming subsector issuing a series of bullish views despite recent selloff. Read more here.